Literature DB >> 10862030

Involvement of the X chromosome in non-Hodgkin lymphoma.

H L McDonald1, R D Gascoyne, D Horsman, C J Brown.   

Abstract

Gain of an X chromosome is observed as a secondary, acquired karyotypic alteration in a significant proportion of malignant lymphomas. To determine the potential involvement of X-linked genes in neoplastic development, we have analyzed the inactivation status of the supernumerary X chromosome in lymphomas in both male and female patients. In males, neither methylation of FMR1 nor expression of XIST was detected, demonstrating that the duplicated chromosome was not subject to inactivation. In females, both expressed polymorphisms and polymorphisms associated with methylation differences between the active and inactive X chromosome were analyzed to determine whether the duplicated chromosome was active or inactive. To facilitate this analysis, allele-specific PCR primers were designed for detection of previously described polymorphisms in the IDSX and G6PD genes. The female lymphomas were shown to be clonal in origin, and duplication of either the active (5 cases) or inactive (4 cases) X chromosome was observed. Correlations between clinical status and the inactivation status of the X chromosome involved in the duplication were not observed in our relatively small sample, although 4/4 informative cases with a t(14;18) showed duplication of the active X chromosome. In the course of these studies, we detected hypermethylation of the androgen receptor (AR) locus in an extremely high proportion of both male (7/9) and female (9/10) samples. These results are discussed with respect to whether sex chromosome aneuploidies in tumors are involved in, or simply the result of, the neoplastic process. Genes Chromosomes Cancer 28:246-257, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862030

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Bisulfite genomic sequencing of microdissected cells.

Authors:  A Kerjean; A Vieillefond; N Thiounn; M Sibony; M Jeanpierre; P Jouannet
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

2.  Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma.

Authors:  Sabine Franke; Iwona Wlodarska; Brigitte Maes; Peter Vandenberghe; Ruth Achten; Anne Hagemeijer; Chris De Wolf-Peeters
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 3.  Physiological roles of long noncoding RNAs: insight from knockout mice.

Authors:  Lingjie Li; Howard Y Chang
Journal:  Trends Cell Biol       Date:  2014-07-09       Impact factor: 20.808

4.  Evidence of a polyclonal nature of myositis ossificans.

Authors:  Andreas Leithner; Andreas Weinhaeusel; Petra Zeitlhofer; Horst Koch; Roman Radl; Reinhard Windhager; Alfred Beham; Oskar A Haas
Journal:  Virchows Arch       Date:  2005-03-11       Impact factor: 4.064

Review 5.  Expression and function of a large non-coding RNA gene XIST in human cancer.

Authors:  Sarah M Weakley; Hao Wang; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

6.  Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.

Authors:  Elahe A Mostaghel; Paul S Martin; Stephen Mongovin; Shani Frayo; Ailin Zhang; Kerstin L Edlefsen; Oliver W Press; Ajay K Gopal
Journal:  Exp Hematol       Date:  2017-01-21       Impact factor: 3.084

7.  Risk Factors of Follicular Lymphoma.

Authors:  Shuangge Ma
Journal:  Expert Opin Med Diagn       Date:  2012-05-08

8.  The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations.

Authors:  Michaël Boudewijns; Jacques J M van Dongen; Anton W Langerak
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

Review 9.  Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review.

Authors:  John Hayslip; Alberto Montero
Journal:  Mol Cancer       Date:  2006-10-06       Impact factor: 27.401

10.  ConteXt of change--X inactivation and disease.

Authors:  Ruben Agrelo; Anton Wutz
Journal:  EMBO Mol Med       Date:  2010-01       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.